Evotec AG today announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/strategic-alliance-with-psychogenics-entered-to-provide-integrated-cns-drug-discovery-solutions-5000
Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated
Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/phase-ii-study-with-nr2b-sub-type-selective-nmda-antagonist-in-treatment-resistant-depression-voluntarily-terminated-4998
Ad hoc: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated
Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-phase-ii-study-with-nr2b-sub-type-selective-nmda-antagonist-in-treatment-resistant-depression-voluntarily-terminated-5593
Evotec reports 54% Q1 revenue growth and significant expansion of drug discovery alliance business
Evotec AG today reported financial results and corporate updates for the first quarter of 2011. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-54-q1-revenue-growth-and-significant-expansion-of-drug-discovery-alliance-business-4996
Twelfth Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received
Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/twelfth–milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-received-4994
Acquisition of Kinaxo Biotechnologies GmbH completed
Evotec AG today announced that it has completed the acquisition of Kinaxo Biotechnologies GmbH, a privately held drug discovery alliance company supporting the development of targeted drugs. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/acquisition-of-kinaxo-biotechnologies-gmbh-completed-4990
Full-Year 2010 Results: A good year with a strong start into 2011
Evotec AG today reported financial results and corporate updates for the year ended 31 December 2010. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/full-year-2010-results-a-good-year-with-a-strong-start-into-2011-4988
Evotec Establishes Research Collaboration With Harvard University and the Howard Hughes Medical Institute in Diabetes Research
Evotec AG today announced the establishment of a research collaboration with Harvard University and the Howard Hughes Medical Institute aimed at discovering and developing new treatments in the field of diabetes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-establishes-research-collaboration-with-harvard-university-and-the-howard-hughes-medical-institute-in-diabetes-research-4984
Evotec to Strengthen its Compound Collection through a Collaboration with ChemBridge
Evotec AG today announced that it has entered into a collaboration with ChemBridge, to further enhance its screening library. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-strengthen-its-compound-collection-through-a-collaboration-with-chembridge-4982